Mayur Resources Limited (ASX:MRL) Announces A$80 Million Equity Raising
Mayur Resources Limited (ASX:MRL) announces an A$80 million equity placement to fund the expansion of its Central Lime Project and enhance working capital.
Imagion Biosystems (ASX:IBX) Starts Manufacturing for Phase 2 HER2+ Breast Cancer Study
Imagion Biosystems (ASX:IBX) commences manufacturing of MagSense® for its Phase 2 HER2+ breast cancer clinical study, advancing its cancer diagnostic platform.
Field Solutions Holdings Limited (ASX:FSG) Continues Suspension from Quotation
ASX continues suspension of Field Solutions Holdings Limited (ASX:FSG) securities due to inadequate financial condition.
First Graphene Limited (ASX:FGR) Raises $2.4M to Accelerate Growth
First Graphene (ASX:FGR) secures $2.4M to boost commercial pipeline and strengthen revenue streams.
Newfield Resources (ASX:NWF) Signs Term Sheet with ACA Resources for Tongo Mine
Newfield Resources (ASX:NWF) enters term sheet with ACA to advance Tongo Mine project in Sierra Leone.
Lunnon Metals Limited (ASX: LM8) Reports High Gold Recoveries at Lady Herial
Lunnon Metals (ASX: LM8) reports a 95% average gold recovery at Lady Herial, highlighting strong potential for future production.
Kaili Resources Limited (ASX:KLR) Selects Drill Sites for Rare Earths Exploration
Kaili Resources Limited (ASX:KLR) selects drill sites for rare earths exploration in South Australia, planning shallow drilling and seeking regulatory approvals.
Poseidon Nickel Limited (ASX:POS) Completes Merger with Horizon Minerals
Poseidon Nickel Limited (ASX:POS) and Horizon Minerals complete their merger through approved schemes of arrangement, leading to Poseidon’s delisting.
Surefire Resources NL (ASX:SRN) Reports High-Grade Metallurgical Test Results for Victory Bore Project
Surefire Resources (ASX:SRN) announces improved metallurgical test results at its Victory Bore project, confirming higher grades and purity of critical minerals.
Neuren Pharmaceuticals (ASX:NEU) Receives FDA Fast Track for NNZ-2591 in Pitt Hopkins Syndrome
Neuren Pharmaceuticals (ASX:NEU) gains FDA Fast Track designation for NNZ-2591 to treat Pitt Hopkins syndrome, following successful Phase 2 trial.